Flemming Bendtsen

Medicine & Life Sciences

1. Fibrosis 100%
2. Portal Hypertension 44%
3. Liver 29%
4. Hepatorenal Syndrome 26%
5. Ascites 25%
6. Crohn Disease 23%
7. Inflammatory Bowel Diseases 22%
8. Ulcerative Colitis 21%
9. Hemodynamics 21%
10. Liver Cirrhosis 19%
11. Terlipressin 18%
12. Liver Diseases 15%
13. Venous Pressure 15%
14. Mortality 12%
15. Kidney 12%
16. Acute-On-Chronic Liver Failure 11%
17. Viscera 11%
18. Inflammation 11%
19. Hemorrhage 11%
20. Transjugular Intrahepatic Portasystemic Shunt 11%
21. Cohort Studies 10%
22. Non-alcoholic Fatty Liver Disease 10%
23. Rifaximin 9%
24. Esophageal and Gastric Varices 9%
25. Cardiomyopathies 9%
26. Portal Pressure 9%
27. Survival 9%
28. Systematic Reviews 9%
29. Population 9%
30. Therapeutics 8%
31. Chronic Pancreatitis 8%
32. Bacterial Translocation 8%
33. Alcoholic Liver Cirrhosis 7%
34. Meta-Analysis 7%
35. Propranolol 7%
36. Biological Therapy 6%
37. Hypovolemia 6%
38. profermin 6%
39. Fatty Liver 6%
40. vedolizumab 6%
41. Randomized Controlled Trials 6%
42. Infliximab 6%
43. Placebos 5%
44. Indocyanine Green 5%
45. Liver Transplantation 5%
46. Confidence Intervals 5%
47. Carvedilol 5%
48. Cardiac Output 5%
49. Hepatic Veins 5%
50. Pancreatitis 5%